Michael J Barnett
Overview
Explore the profile of Michael J Barnett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
522
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barnett M, Millane R, Kingston R
Acta Crystallogr D Struct Biol
. 2024 Oct;
80(Pt 11):800-818.
PMID: 39441251
For protein crystals in which more than two thirds of the volume is occupied by solvent, the featureless nature of the solvent region often generates a constraint that is powerful...
2.
Barnett M, Kingston R
J Appl Crystallogr
. 2024 Apr;
57(Pt 2):492-498.
PMID: 38596730
Hendrickson & Lattman [ (1970), B, 136-143] introduced a method for representing crystallographic phase probabilities defined on the unit circle. Their approach could model the bimodal phase probability distributions that...
3.
Barnett M, Pinheiro J, Keown J, Biboy J, Gray J, Lucinescu I, et al.
PLoS Pathog
. 2023 Aug;
19(8):e1011563.
PMID: 37585473
Trichomonas vaginalis is a human protozoan parasite that causes trichomoniasis, a prevalent sexually transmitted infection. Trichomoniasis is accompanied by a shift to a dysbiotic vaginal microbiome that is depleted of...
4.
Kodad S, Sutherland H, Limvorapitak W, Abou Mourad Y, Barnett M, Forrest D, et al.
Clin Lymphoma Myeloma Leuk
. 2019 Nov;
19(12):784-790.
PMID: 31678079
Background: Autologous stem cell transplant (ASCT) is the preferred consolidation strategy to treat eligible patients with multiple myeloma (MM) and related plasma cell dyscrasias. Given the increasing volume of patients...
5.
Keown J, Black M, Ferron A, Yap M, Barnett M, Pearce F, et al.
J Biol Chem
. 2018 Oct;
293(47):18378-18386.
PMID: 30282803
The retroviral restriction factor tripartite motif-containing 5α (Trim5α) acts during the early postentry stages of the retroviral life cycle to block infection by a broad range of retroviruses, disrupting reverse...
6.
Limvorapitak W, Barnett M, Hogge D, Forrest D, Nevill T, Narayanan S, et al.
Clin Lymphoma Myeloma Leuk
. 2018 Aug;
18(11):e481-e491.
PMID: 30100330
Introduction: Optimal post-remission therapy (PRT) for intermediate risk acute myeloid leukemia remains an area of ongoing research. We aimed to retrospectively compare outcomes following autologous stem cell transplantation (autoSCT) with...
7.
Zhu K, Song K, Connors J, Leitch H, Barnett M, Ramadan K, et al.
Br J Haematol
. 2018 May;
181(6):782-790.
PMID: 29741758
Treatment of Burkitt lymphoma (BL) with intensive, multi-agent chemotherapy with aggressive central nervous system (CNS) prophylaxis results in high cure rates, although no regimen is standard of care. We examined...
8.
Nair A, Barnett M, Broady R, Hogge D, Song K, Toze C, et al.
Biol Blood Marrow Transplant
. 2015 Apr;
21(8):1437-44.
PMID: 25865648
Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only known curative therapy for chronic myeloid leukemia (CML); however, it is rarely utilized given the excellent long-term results with tyrosine kinase...
9.
Sun H, Savage K, Karsan A, Slack G, Gascoyne R, Toze C, et al.
Clin Lymphoma Myeloma Leuk
. 2015 Feb;
15(6):341-8.
PMID: 25656914
Background: Double-hit lymphoma is characterized by the presence of concurrent MYC (myelocytomatosis oncogene) and BCL2 (B-cell lymphoma 2) gene rearrangements. Prognosis is poor with standard chemoimmunotherapy. Since 2003, the British...
10.
Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest D, Chan M, et al.
J Natl Cancer Inst
. 2013 Mar;
105(6):405-23.
PMID: 23446755
Background: Imatinib mesylate (IM) induces clinical remission of chronic myeloid leukemia (CML). The Abelson helper integration site 1 (AHI-1) oncoprotein interacts with BCR-ABL and Janus kinase 2 (JAK2) to mediate...